Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
\Neuroprotection: Reduces glutamate excitotoxicity, supporting brain health
1 (Springer, 2014)
When a compound has such a narrow target, the potential for off-target side effects is inherently limited
Its two RLT products Lutathera (lutetium-177 DOTATATE) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and Pluvicto (lutetium-177 PSMA-617) for metastatic castration-resistant prostate cancer represent the most commercially advanced radioligand therapy platform in the world and occupy the Oncology Peptide Therapy segment, which the report forecasts to grow at 11.79% CAGR through 2031
US$ 29.53
US$ 28.33
US$ 28.52
US$ 25.00
US$ 20.06
US$ 27.88
US$ 26.93
